Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Eli Lilly and Novo Nordisk dominate the ... agonist candidate in phase 2 trials at the moment. Lilly's leap closer to the finish line But Lilly is ahead of the pack and just took a leap closer ...

Eli Lilly and Company is shifting away from using horseshoe ... except that we can make it in cells and we don’t need to derive that from horseshoe crab blood. This is a kind of a more recent ...

a cutting-edge cancer treatment that targets specific cancer cells. This is just one example of the company’s diverse and promising pipeline. Eli Lilly and Company (NYSE:LLY) holds a strong ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Eli Lilly is cracking down. "Anyone continuing to sell mass compounded tirzepatide is breaking the law and deceiving patients," Lilly said in a company statement sent to NPR. "We will continue to ...

From late 2020 to the summer of 2024, Eli Lilly ... 2016, Lilly’s revenue grew by 60% but income grew by 91%. Typically, you would not expect a company growing at its top line by 7% annually ...

Eli Lilly is cracking down. "Anyone continuing to sell mass compounded tirzepatide is breaking the law and deceiving patients," Lilly said in a company statement sent to NPR. "We will continue to take ...